Aytu Biopharma (AYTU) Operating Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has reported Operating Expenses for 17 consecutive years, with $11.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Operating Expenses rose 12.31% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $51.8 million, a 5.53% increase from a year earlier, with the FY2025 full-year figure at $53.7 million, up 5.95% from the prior year.
• Operating Expenses was $11.7 million for Q1 2026 at Aytu Biopharma, up from $11.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $66.1 million in Q1 2022 and troughed at $10.4 million in Q1 2025.
• A 5-year average of $18.8 million and a median of $13.3 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 2179.55% in 2022 and sank 67.78% in 2023, its largest moves.
• Over 5 years, Operating Expenses stood at $24.2 million in 2022, then tumbled by 52.58% to $11.5 million in 2023, then gained by 8.94% to $12.5 million in 2024, then dropped by 7.11% to $11.6 million in 2025, then advanced by 0.6% to $11.7 million in 2026.
• The last three Operating Expenses figures came in at $11.7 million (Q1 2026), $11.6 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.